Neos Therapeutics Inc (NASDAQ:NEOS)’s share price shot up 6.3% during mid-day trading on Tuesday . The company traded as high as $1.89 and last traded at $1.85, 195,900 shares traded hands during mid-day trading. A decline of 46% from the average session volume of 366,161 shares. The stock had previously closed at $1.74.
A number of equities analysts have recently commented on NEOS shares. BMO Capital Markets cut their price objective on shares of Neos Therapeutics from $4.00 to $3.00 and set a “market perform” rating for the company in a research report on Monday, August 12th. Zacks Investment Research lowered shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. ValuEngine raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald lowered their target price on shares of Neos Therapeutics from $20.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 12th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $6.05.
The company has a market cap of $86.53 million, a P/E ratio of -1.16 and a beta of 0.93. The company has a 50 day moving average of $1.67 and a 200-day moving average of $1.88. The company has a debt-to-equity ratio of 41.70, a current ratio of 1.13 and a quick ratio of 0.91.
Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Thursday, August 8th. The company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.09. The business had revenue of $15.64 million for the quarter, compared to analysts’ expectations of $16.70 million. Research analysts anticipate that Neos Therapeutics Inc will post -0.5 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Stonepine Capital Management LLC increased its position in shares of Neos Therapeutics by 10.2% in the second quarter. Stonepine Capital Management LLC now owns 4,971,014 shares of the company’s stock worth $6,413,000 after purchasing an additional 459,510 shares during the last quarter. Paloma Partners Management Co bought a new stake in Neos Therapeutics during the second quarter valued at approximately $275,000. Alambic Investment Management L.P. lifted its position in Neos Therapeutics by 1,710.7% during the second quarter. Alambic Investment Management L.P. now owns 219,090 shares of the company’s stock valued at $283,000 after purchasing an additional 206,990 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Neos Therapeutics by 1,790.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 215,900 shares of the company’s stock worth $261,000 after buying an additional 204,481 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in Neos Therapeutics by 332.1% in the 2nd quarter. Jane Street Group LLC now owns 165,503 shares of the company’s stock worth $213,000 after buying an additional 127,202 shares in the last quarter. Hedge funds and other institutional investors own 45.86% of the company’s stock.
About Neos Therapeutics (NASDAQ:NEOS)
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Featured Article: What is the formula for the cash asset ratio?
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.